S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff election
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff election
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff election
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
MarketBeat Week in Review – 5/22 - 5/26
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Baby eels remain one of America's most valuable fish after strong year in Maine
China's 1st domestically made passenger plane completes maiden commercial flight
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
EgyptAir flight from Cairo blows tire during landing in Saudi Arabia
'Succession' fans brace for series finale of Emmy-winning hit drama
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Voters in Turkey choose between Erdogan and Kilicdaroglu in presidential runoff election
Russia launched 'largest drone attack' on Ukrainian capital before Kyiv Day; 1 killed
NASDAQ:AVXL

Anavex Life Sciences (AVXL) Competitors

$9.32
+0.36 (+4.02%)
(As of 05/26/2023 ET)
Compare
Today's Range
$8.95
$9.36
50-Day Range
$7.66
$9.50
52-Week Range
$7.36
$15.24
Volume
960,729 shs
Average Volume
858,953 shs
Market Capitalization
$753.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.60

AVXL vs. IMTX, NVAX, EDIT, ALEC, TWST, HLVX, ALLO, RGNX, FDMT, and MESO

Should you be buying Anavex Life Sciences stock or one of its competitors? The main competitors of Anavex Life Sciences include Immatics (IMTX), Novavax (NVAX), Editas Medicine (EDIT), Alector (ALEC), Twist Bioscience (TWST), HilleVax (HLVX), Allogene Therapeutics (ALLO), REGENXBIO (RGNX), 4D Molecular Therapeutics (FDMT), and Mesoblast (MESO). These companies are all part of the "biological products, except diagnostic" industry.

Anavex Life Sciences vs.

Anavex Life Sciences (NASDAQ:AVXL) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Immatics has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anavex Life SciencesN/AN/A-$47.98 million-$0.68-13.71
Immatics$182.13 million4.15$39.53 million-$1.06-9.29

Anavex Life Sciences presently has a consensus target price of $42.60, indicating a potential upside of 357.08%. Immatics has a consensus target price of $19.75, indicating a potential upside of 100.51%. Given Anavex Life Sciences' higher possible upside, equities analysts clearly believe Anavex Life Sciences is more favorable than Immatics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Anavex Life Sciences
0 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.75
Immatics
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00

Anavex Life Sciences has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Anavex Life Sciences has a net margin of 0.00% compared to Immatics' net margin of -85.93%. Anavex Life Sciences' return on equity of -36.78% beat Immatics' return on equity.

Company Net Margins Return on Equity Return on Assets
Anavex Life Sciences N/A -36.78% -34.00%
Immatics -85.93% -41.31% -17.89%

31.2% of Anavex Life Sciences shares are held by institutional investors. Comparatively, 29.1% of Immatics shares are held by institutional investors. 11.6% of Anavex Life Sciences shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Immatics had 2 more articles in the media than Anavex Life Sciences. MarketBeat recorded 7 mentions for Immatics and 5 mentions for Anavex Life Sciences. Immatics' average media sentiment score of 0.82 beat Anavex Life Sciences' score of 0.45 indicating that Immatics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Anavex Life Sciences
1 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Immatics
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Anavex Life Sciences received 396 more outperform votes than Immatics when rated by MarketBeat users. Likewise, 74.20% of users gave Anavex Life Sciences an outperform vote while only 70.59% of users gave Immatics an outperform vote.

CompanyUnderperformOutperform
Anavex Life SciencesOutperform Votes
420
74.20%
Underperform Votes
146
25.80%
ImmaticsOutperform Votes
24
70.59%
Underperform Votes
10
29.41%

Summary

Anavex Life Sciences beats Immatics on 9 of the 17 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVXL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVXL vs. The Competition

MetricAnavex Life SciencesBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$753.43M$2.57B$4.57B$6.43B
Dividend YieldN/A2.33%2.43%6.61%
P/E Ratio-13.718.27132.9014.47
Price / SalesN/A183.143,681.4494.24
Price / CashN/A15.9594.26104.96
Price / Book5.184.895.037.13
Net Income-$47.98M$53.60M$118.58M$192.86M
7 Day Performance-1.38%-0.14%1.09%0.19%
1 Month Performance13.80%7.78%5.72%2.41%
1 Year Performance-4.02%10.15%19.40%-0.23%

Anavex Life Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMTX
Immatics
1.4645 of 5 stars
$9.80
-1.9%
$19.75
+101.5%
+34.9%$751.37M$182.13M-9.25188Short Interest ↑
NVAX
Novavax
2.1152 of 5 stars
$7.99
+6.0%
$65.57
+720.7%
-87.0%$689.62M$1.98B-0.561,992Analyst Downgrade
EDIT
Editas Medicine
1.8819 of 5 stars
$9.58
-0.6%
$15.33
+60.1%
-22.1%$661.02M$19.71M-3.01264Short Interest ↑
ALEC
Alector
2.1648 of 5 stars
$7.75
+1.0%
$15.13
+95.2%
-17.5%$645.96M$133.62M-4.78208Short Interest ↑
TWST
Twist Bioscience
2.2376 of 5 stars
$14.92
-0.1%
$26.17
+75.4%
-59.9%$852.68M$203.57M-3.96652News Coverage
HLVX
HilleVax
1.2199 of 5 stars
$15.88
-2.0%
$32.00
+101.5%
+75.8%$622.50MN/A-4.2315
ALLO
Allogene Therapeutics
2.277 of 5 stars
$6.05
-0.7%
$16.50
+172.7%
-30.9%$882.33M$240,000.00-2.48308
RGNX
REGENXBIO
2.1099 of 5 stars
$20.39
-0.7%
$40.00
+96.2%
-16.4%$886.35M$112.72M-3.27372Positive News
FDMT
4D Molecular Therapeutics
1.9805 of 5 stars
$17.98
-1.9%
$34.13
+89.8%
+130.5%$598.02M$3.13M-5.32124
MESO
Mesoblast
2.2805 of 5 stars
$3.67
-3.4%
$10.13
+175.9%
+0.6%$597.62M$10.21M-5.9283Upcoming Earnings
Short Interest ↓

Related Companies and Tools

This page (NASDAQ:AVXL) was last updated on 5/28/2023 by MarketBeat.com Staff

My Account -